Combination chemotherapy for ovarian cancer--lessons not yet learned?

被引：0
作者：
Kaye S.B. [1 ]
机构：
[1] CRC, Department of Medical Oncology, Royal Marsden Hospital, Downs Road, Sutton
来源：
Current Oncology Reports | 2002年 / 4卷 / 3期
关键词：
Ovarian Cancer; Epidermal Growth Factor Receptor; Paclitaxel; Carboplatin; Epidermal Growth Factor Receptor Expression;
D O I：
10.1007/s11912-002-0013-3
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：185 / 186
页数：1
相关论文
共 8 条
  • [1] Thigpen JT(2000)Chemotherapy for advanced ovarian cancer: overview of randomized trials Semin Oncol 27 11-16
  • [2] Muggia FM(2000)Phase III randomized trial of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with advanced ovarian cancer: a GOG study J Clin Oncol 18 106-115
  • [3] Brady PS(2000)Randomized trial of paclitaxel and carboplatin versus a control arm of carboplatin or CAP (ICON 3) [abstract] Proc ASCO 19 379a-379a
  • [4] Brady MF(2001)Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian cancer [abstract] Proc ASCO 20 208a-208a
  • [5] Colombo N(undefined)undefined undefined undefined undefined-undefined
  • [6] Finkler N(undefined)undefined undefined undefined undefined-undefined
  • [7] Gordon A(undefined)undefined undefined undefined undefined-undefined
  • [8] Crozier M(undefined)undefined undefined undefined undefined-undefined
1